<DOC>
	<DOCNO>NCT01035983</DOCNO>
	<brief_summary>In open-label , multi-center study , patient treat frovatriptan maximum 12 perimenstrual period ( PMPs ) . For PMP , dose commence 2 day anticipate onset menstrual migraine ( MM ) headache continue total 6 day . Patients take load dose frovatriptan 5 mg ( two tablet ) twice daily Day 1 , follow frovatriptan 2.5 mg twice daily Days 2-6 . During study , patient visit study site total 6 time . Efficacy and/or safety assessment perform visit .</brief_summary>
	<brief_title>Safety Tolerability Frovatriptan Prevention Menstrually Associated Migraine ( MAM ) Headaches</brief_title>
	<detailed_description>This Phase IIIb , open label , multi-centre study evaluate safety tolerability frovatriptan take patient 12 perimenstrual period ( PMPs ) prevention menstrual migraine ( MM ) . The study require approximately 300 patient treat 6 PMPs 100 patient treat 12 PMPs . To achieve number , 550 patient enrol study . Once enrolled , patient request treat least 6 PMPs first 9 month 12 PMPs overall . Patients remain study maximum 15 month complete treatment 12 PMPs , whichever occur sooner.Patients take load dose frovatriptan 5 mg ( two tablet ) twice daily Day 1 , follow frovatriptan 2.5 mg twice daily Days 2-6 .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Frovatriptan</mesh_term>
	<criteria>Female age 15 year ( â‰¥18 year United Kingdom South Africa ) , least 12 month document history experience migraine accord IHS criterion , include confirmation 3 month diary base documented history MAM . An average frequency MAM least two three menstrual cycle , within previous 12 month Regular , predictable menstrual period MAM headache occur Day 2 day +4 menses Able willing sign inform consent comply study procedure , include completion diary card . More three migraine attack per month MAM attack A history myocardial infarction , ischemic heart disease ( present symptom sign compatible ischemic heart disease ) , coronary vasospasm peripheral vascular disease Significant cerebrovascular disease include basilar hemiplegic migraine Uncontrolled hypertension ( SBP &gt; 180 mmHg , DBP &gt; 95 mmHg ) Severe hepatic renal insufficiency More 15 headache day per month , exclusive migraine headache Any condition serious illness , opinion investigator , would interfere optimal participation study A history clinically relevant allergy , include frovatriptan triptans Pregnant breastfeeding , intend become pregnant breastfeed study period ( patient use adequate contraception negative pregnancy test screening ) Treatment another investigational drug within 30 day 5 halflives ( whichever longer ) screen visit Any change oral contraceptive medication ( applicable ) 2 month prior screen , anticipation change study participation Any change type dose prophylactic migraine medication 2 month prior screen , anticipation change study participation A history migraine aura , accord IHS criterion , currently treat combine oral contraceptive ( South Africa ) .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>menstrually associate migraine ( MAM ) , Migraines , Menstrual Migraines , menstrually relate migraine</keyword>
</DOC>